[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopausal-complaints\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopausal-complaints":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,78,118,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100625809","amygdala-insula-retraining-in-the-management-of-perimenopause-symptoms-100625809",false,"NCT07427459","Amygdala Insula Retraining in the Management of Perimenopause Symptoms","Inclusion Criteria:\n\n* Experiencing perimenopausal symptoms\n* Meets STRAW+10 criteria based on self-assessment (-2 to +1c)\n* Able to read and understand English\n* Access to internet\n\nExclusion Criteria:\n\n* Pregnancy\n* Presence of a severe psychiatric condition requiring immediate clinical intervention\n* Uncontrolled thyroid disease or prolactinoma\n* Active cancer treatment\n* Inability to provide informed consent\n* Any medical or psychiatric condition that, in the judgment of the investigator or study team, would interfere with safe participation or study completion","FEMALE","38 Years","60 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to evaluate a neuroplasticity-based mind-body intervention, Amygdala and Insula Retraining (AIR), compared to a wait-list control in individuals experiencing perimenopausal symptoms.\n\nOur research questions include:\n\nDoes AIR reduce overall perimenopausal symptom burden compared to a wait-list control?\n\nDoes AIR improve sleep disturbance, vasomotor symptom interference, fatigue, mood, anxiety, and quality of life in perimenopausal individuals?\n\nAre symptom changes associated with improvements in autonomic regulation and sleep parameters, as reflected by exploratory wearable measures including heart rate variability?",[26,27],"Perimenopause","Menopausal Complaints",[29],"Amygdala and Insula Retraining (AIR)","RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":20},"2026-07-15",{"date":38,"type":20},"2027-03-01",{"name":40,"class":41},"Chronic Conditions Research Fund","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":51,"maxAge":17,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100643860","multidimensional-determinants-of-functional-health-in-women-aged-45-60-100643860","NCT07667699","Multidimensional Determinants of Functional Health In Women Aged 45-60","Multidimensional Determinants and Structural Foundations of Functional Health In Women Aged 45-60: The Role of Muscle and Bone Health","Inclusion Criteria are:\n\n* Women aged 45 to 60 years\n* Ability to read and complete study questionnaires\n* Provision of written informed consent\n* Ability to complete physical performance assessments\n\nExclusion Criteria are:\n\n* Acute systemic illness\n* Active malignancy\n* Severe neurological or orthopedic impairment limiting physical performance assessment\n* Cognitive impairment precluding informed consent or questionnaire completion",true,"45 Years",{"count":53,"type":20},200,"1 Day","OBSERVATIONAL","The goal of this observational study is to learn about the multidimensional determinants of functional health in women aged 45 to 60 years. The study will focus on the role of muscle strength, bone mineral density, body composition, physical activity, sleep quality, depressive symptoms, and menopause-related symptoms in functional health.\n\nThe main questions it aims to answer are:\n\n1. Does muscle strength contribute to functional health in women aged 45 to 60 years?\n2. Does bone mineral density contribute to functional health in women aged 45 to 60 years?\n3. How are physical activity, sleep quality, depressive symptoms, body composition, and menopause-related quality of life associated with functional health?\n\nParticipants will:\n\n* Undergo handgrip strength measurement\n* Perform a 30-second chair stand test\n* Undergo bone mineral density and body composition assessment\n* Complete questionnaires about physical activity, sleep quality, depressive symptoms, menopausal symptoms, and quality of life\n* Provide demographic and clinical information",[58,59,27,60,61,62,63],"Healthy","Perimenopausal Depression","Bone Mineral Density","Sarcopenia","Sleep Quality","Quality of Life",[65,26,66,61,62,67],"Menopause","Bone mineral density","Quality of life","NOT_YET_RECRUITING","2026-06-19",{"date":71,"type":34},"2026-06-25",{"date":73,"type":20},"2026-06-15",{"date":75,"type":20},"2026-12-31",{"name":77,"class":41},"Kartal City Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":88,"studyType":55,"phases":4,"briefSummary":89,"conditions":90,"keywords":99,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100638708","a-retrospective-and-prospective-clinical-registry-for-data-collection-of-perimenopausal-menopausal-and-premature-ovarian-insufficiency-women-100638708","NCT07606326","A Retrospective and Prospective Clinical Registry for Data Collection of Perimenopausal, Menopausal and Premature Ovarian Insufficiency Women","Inclusion Criteria:\n\n* 1\\. Age: women aged 18-60 years at the time of enrollment and in follow up, up to 65 years old\n* 2\\. Women in Perimenopause, defined as the transitional period preceding the final menstrual period, characterized by changes in menstrual cycle regularity and\u002For the onset of menopausal symptoms. Women experience variable cycle length, skipped cycles, or amenorrhea of less than 12 months' duration, often accompanied by vasomotor symptoms, sleep disturbances, and other menopause-related complaints.\n* 3\\. Women in Menopause, defined as the permanent cessation of menstruation resulting from loss of ovarian follicular activity and is diagnosed retrospectively after 12 consecutive months of amenorrhea in the absence of other pathological or physiological causes. Women may present with persistent menopausal symptoms and\u002For long-term consequences of estrogen deficiency, including changes in bone, cardiovascular, metabolic, and genitourinary health.\n\nlt includes women in early Menopause, defined as menopause occurring before the age of 45 years, but after 40 years, in the absence of surgical or iatrogenic causes.\n\n* 4\\. Women in Premature Ovarian lnsufficiency (POI), defined as impaired ovarian function occurring before the age of 40 years, characterized by oligo- or amenorrhea, elevated gonadotropin levels, and hypoestrogenism.\n* 5\\. Women with iatrogenic menopause, caused by:\n* Bilateral oophorectomy\n* Chemotherapy or radiotherapy-induced ovarian failure\n* Other pharmacological treatments resulting in ovarian insuftficiency\n* 6\\. Women evaluated at the specialized Menopause Clinic or the Multidisciplinary Endocrinology\u002FMetabolic Disorders clinic.\n* 7\\. Data availability: for retrospective participants, sufficient medical records must be available; tor prospective participants, patients must be willing to participate in the registry and provide informed consent.\n* 8\\. All women are eligible regardless of concomitant diseases, to reflect real-world clinical practice.\n\nExclusion Criteria:\n\n* 1\\. Women unable to provide informed consent due to cognitive impairment or severe psychiatric conditions.\n* 2\\. Women already participating in interventional clinical trials affecting menopausal or metabolic management in a way that could bias observational data.\n* 3\\. Women with incomplete medical records for retrospective data collection or those refusing informed consent for prospective enrollment.","18 Years","65 Years",{"count":87,"type":20},5000,"20 Years","This study is designed as on observational, retrospective, and prospective clinical registry aimed at collecting comprehensive real-world data on women in perimenopause, menopause, and with premature ovarian insufficiency (POI) attending a specialized Menopause Clinic and a Multidisciplinary Outpatient Clinic dedicated to Endocrinology and Metabolic Disorders.\n\nThe registry comprises both retrospective data, extracted from the medical records of eligible patients evaluated from January 2000 onward, and prospective data, which will be continuously collected for all newly referred patients up to 2040. This combined design allows the longitudinal observation of clinical characteristics, management strategies, and health outcomes across different stages of the menopausal transition and premature ovarian insufficiency within routine clinical practice.\n\nClinical management and therapeutic strategies, including hormone replacement therapy and non-hormonal interventions, will be documented. Laboratory data, as well as imaging data routinely used in clinical practice, will be recorded when available.\n\nEnrolled patients will undergo a personalized follow-up schedule based on clinical findings and the conclusions of each visit, in accordance with standard clinical practice. Follow-up visits may be scheduled annually for routine monitoring or at shorter intervals (semi-annual or quarterly) in the presence of conditions requiring closer clinical surveillance.\n\nThe registry is intended to reflect real-world clinical practice and to support the descriptive evaluation of patterns of care, symptom burden, and longitudinal clinical outcomes in women undergoing the menopausal transition or affected by premature ovarian insufficiency. The collected data will provide a structured platform for epidemiological analyses and hypothesis-generating observational research aimed at improving the understanding and management of menopausal health and associated endocrine and metabolic conditions.",[65,91,92,93,27,94,95,96,97,98],"Menopausal Hormone Therapy","Menopause Surgical","Menopause Related Conditions","Menopausal Osteoporosis","Menopause-related Hot Flashes","Menopausal and Perimenopausal Disorder, Unspecified","Menopausal and Postmenopausal Women","Premature Ovarian Failure (POF)",[100,101,102,103,104,105,106,107,108],"menopause","perimenopause","premature ovarian failure","hormonal replacement teraphy","osteoporosis","genitourinary syndrome of menopause","hot flashes","menopausal discomfort","menopausal symptoms","2026-05-19",{"date":111,"type":34},"2026-05-26",{"date":113,"type":20},"2026-06",{"date":115,"type":20},"2040-12",{"name":117,"class":41},"IRCCS San Raffaele",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":50,"sex":15,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":42},"100633458","phase-4-vaginal-estradiol-vs-moisturizer-to-improve-postmenopausal-vaginal-aging-symptoms-and-the-microbiome-in-women-living-with-hiv-100633458","NCT07526948","Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV","Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV","Inclusion Criteria:\n\n* female\n* at least 40 years old\n* menopausal (no menses in 12 months) within 2 years of last menstrual period or perimenopausal in the late menopausal transition, defined as an interval of amenorrhea greater than or equal to 60 days\n* have symptoms of the genitourinary syndrome of menopause (GSM) which developed within the prior 2 years. Symptoms of GSM include vaginal symptoms including dryness, soreness, itching, irritation and dyspareunia and\u002For urinary symptoms including urgency, frequency and recurrent urinary tract infections (UTIs)\n\nExclusion Criteria:\n\n* Unexplained or unevaluated abnormal genital bleeding\n* Current or suspected pregnancy\n* Desired pregnancy\n* If less than 55 years old, have had a hysterectomy and have at least one ovary (as menopause cannot be determined in this case by amenorrhea alone)\n* Pelvic or vaginal surgery in the prior 60 days\n* Used systemic reproductive hormones in the last 2 months\n* Used antibiotics in the last 30 days\n* Used immunosuppressive medications in the prior 60 days including biologics, chemotherapeutics or post transplant immunosuppressive medications\n* Used any vaginal or vulvar preparations in the last month\n* Current active vaginal infection diagnosed at study entry\n* Any serious disease or condition that may interfere with study compliance\n* Current or previous history of breast cancer or estrogen dependent cancer (e.g., ovarian, endometrial)\n* Current or previous history of deep vein thrombosis or pulmonary embolism\n* Current or previous history of myocardial infarction or stroke\n* Known clotting disorder including Protein C, Protein S and antithrombin deficiency, Factor V Leiden or prothrombin mutations\n* Known severe liver disease including cirrhosis or active Hepatitis B\n* Known allergic reaction to Vagifem (estradiol vaginal tablet) or Replens","40 Years","70 Years",{"count":128,"type":20},62,[130],"PHASE4","This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.",[27,133,134,135,93,136,26],"Vaginal Atrophy","Genitourinary Symptoms","HIV (Human Immunodeficiency Virus)","Vaginitis",[138,139,140,141,65,142,143,144,145,146,147,148],"Pain with sex","Vaginal dryness","Symptoms of menopause","HIV Infection","Vaginal microbiome","Dysbiosis","Aging","Premature aging","Atrophic vaginitis","Genitourinary syndrome of menopause (GSM)","Symptoms of perimenopause","2026-04-08",{"date":151,"type":34},"2026-04-14",{"date":153,"type":20},"2026-06-01",{"date":155,"type":20},"2031-06-30",{"name":157,"class":41},"Albert Einstein College of Medicine",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":85,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":42},"100503165","the-influence-of-hormone-replacement-therapy-and-supervised-exercise-training-on-body-composition-cardiovascular-risk-and-insulin-sensitivity-in-postmenopausal-women-100503165","NCT05831709","The Influence of Hormone Replacement Therapy and Supervised Exercise Training on Body Composition, Cardiovascular Risk and Insulin Sensitivity in Postmenopausal Women","De Invloed Van Hormoonsubstitutietherapie en Gesuperviseerde Training op Lichaamssamenstelling, Cardiovasculair Risico en Insulinegevoeligheid Bij Postmenopauzale Vrouwen","OPERATE","Inclusion Criteria:\n\n* Postmenopausal women (diagnosed by physician) with complaints due to menopause\n* Indication for hormonal substitution therapy (except for the control group)\n* Good general health\n* BMI: 20-30 kg\u002Fm2\n* Only the use of cholesterol-, blood pressure- or\u002Fand thyroid-regulating medication is permitted",{"count":167,"type":20},390,[23],"This trial investigates whether supervised training in combination with hormonal substitution therapy has an impact on body composition, cardiovascular risk, risk for dementia, osteoporosis and insulin sensitivity in postmenopausal women.",[171,27],"Postmenopause","2025-11-14",{"date":174,"type":34},"2025-11-18",{"date":176,"type":34},"2023-05-12",{"date":178,"type":20},"2028-12",{"name":180,"class":41},"University Hospital, Ghent"]